NC-KBI-BIOPHARM/ARGONAUT
16.1.2024 13:58:26 CET | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and diagnostics industries, today announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions. The arrangement provides a seamless integration of drug substance and drug product manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish. The alliance reinforces both companies’ commitment to support customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116635207/en/
Biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.
“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development,” said J.D. Mowery, President and CEO of KBI Biopharma.
He continued, “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”
“We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations,” said Wayne Woodard, Founder and CEO of Argonaut. “Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products. With this collaboration, biopharmaceutical organizations can now seamlessly move from development to full-scale manufacturing, saving both time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
More information available at www.argonautms.com.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116635207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“AI Realized Through Display” … Samsung Display Showcases AI-Optimized OLED Technologies at MWC262.3.2026 10:58:00 CET | Press release
Introducing “Flex Magic Pixel™,” a panel-integrated privacy technology enabled by low-power, high-brightness LEAD™… Essential smartphone privacy for the AI era’s surge in personalized data usage “Thinner and tougher”… Foldable OLED durability proven with a golf putting challenge “Create your own K-pop concert”… MR experience equipped with 5,000 PPI RGB OLEDoS draws major attention New concept “edge devices” incorporating Samsung Display OLED’s unique free-form, low-power and high-resolution technologies unveiled – including the companion robot concept “Mini PetBot” and the interior décor item “AI Toy House” Spain’s Park Güell tile mosaics recreated through displays using 6.8-inch OLED and 27-inch QD-OLED, highlighting high color reproduction and bezel-less technology Eric Kim, Executive Vice President and Head of Mobile Strategic Marketing: “In the AI era, displays will evolve from simple viewing screens into intelligent interfaces that understand and respond to users and their surroun
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio2.3.2026 09:00:00 CET | Press release
Radiobotics to join Medimaps Group, creating a global provider of AI-driven musculoskeletal (MSK) medical imaging software The transaction is expected to close following receipt of Danish foreign direct investment (FDI) approval and other customary closing conditions Together, they will bridge the gap between preventative bone health and acute trauma diagnostics, offering an expanded portfolio across X-ray and DXA: Fracture detection, opportunistic bone fragility assessment, and fracture risk prediction The combined entity will have a commercial reach in 90 countries through a robust network of direct and partner channels Both organizations will maintain their established brands, supported by close R&D and commercial collaboration Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, and Radiobotics ApS, a leader in AI-powered MSK radiology solutions, today announced that they have entered into a strategic merger agreement. Closing of the transacti
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera2.3.2026 08:00:00 CET | Press release
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In addi
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants2.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the expansion of its 5G RedCap portfolio with the launch of the RM255C-GL for global markets and the RG255C-NA for the North America market, further strengthening its mid-tier 5G offering for worldwide deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301754857/en/ Quectel expands mid-tier 5G portfolio with new RedCap 3GPP release 17 variants As 5G expands further into industrial and IoT domains, the need for solutions that combine strong performance with cost efficiency is becoming increasingly critical. Positioned between high-speed eMBB and narrowband NB-IoT, 5G RedCap (Reduced Capability) has emerged as the ideal technology to address this mid-tier connectivity gap. With a comprehensive product portfolio and global deployment expertise, Quectel enables a seamless transition for mid-speed IoT applications moving toward sca
Thales sets a world first in quantum-safe security for 5G networks2.3.2026 08:00:00 CET | Press release
Thales has successfully demonstrated a world-first innovation that prepares 5G networks for the age of quantum computing, marking a major milestone for the global telecommunications industry. The collaboration with a top tier mobile operator, showed that existing 5G SIM / eSIM cards already deployed in the field can be securely upgraded to quantum-safe protection, without disrupting service or impacting the customer experience. This Post-Quantum Cryptographic (PQC) breakthrough proves that mobile networks can evolve their security through crypto agility to address quantum cyber threats. Quantum computing has the potential to break today’s encryption methods in the future, putting mobile communications, personal data and critical infrastructure at risk. For telecom operators, this is not a distant theoretical issue: 5G networks underpin everything from smartphones and connected vehicles to emergency services, industry and national infrastructure. This press release features multimedia.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom